Assessment of cancer cell‐expressed <scp>HLA class I</scp> molecules and their immunopathological implications

DOI Web Site 参考文献138件
  • Terufumi Kubo
    Department of Pathology School of Medicine, Sapporo Medical University Sapporo Japan
  • Shiori Asano
    Department of Pathology School of Medicine, Sapporo Medical University Sapporo Japan
  • Kenta Sasaki
    Department of Pathology School of Medicine, Sapporo Medical University Sapporo Japan
  • Kenji Murata
    Department of Pathology School of Medicine, Sapporo Medical University Sapporo Japan
  • Takayuki Kanaseki
    Department of Pathology School of Medicine, Sapporo Medical University Sapporo Japan
  • Tomohide Tsukahara
    Department of Pathology School of Medicine, Sapporo Medical University Sapporo Japan
  • Yoshihiko Hirohashi
    Department of Pathology School of Medicine, Sapporo Medical University Sapporo Japan
  • Toshihiko Torigoe
    Department of Pathology School of Medicine, Sapporo Medical University Sapporo Japan

書誌事項

公開日
2024-05
資源種別
journal article
権利情報
  • http://creativecommons.org/licenses/by-nc-nd/4.0/
DOI
  • 10.1111/tan.15472
公開者
Wiley

この論文をさがす

説明

<jats:p>Immunotherapy using immune checkpoint inhibitors (ICIs) has shown superior efficacy compared with conventional chemotherapy in certain cancer types, establishing immunotherapy as the fourth standard treatment alongside surgical intervention, chemotherapy, and radiotherapy. In cancer immunotherapy employing ICIs, CD8‐positive cytotoxic T lymphocytes are recognized as the primary effector cells. For effective clinical outcomes, it is essential that the targeted cancer cells express HLA class I molecules to present antigenic peptides derived from the tumor. However, cancer cells utilize various mechanisms to downregulate or lose HLA class I molecules from their surface, resulting in evasion from immune surveillance. Correlations between prognosis and the integrity of HLA class I molecules expressed by cancer cells have been consistently found across different types of cancer. This paper provides an overview of the regulatory mechanisms of HLA class I molecules and their role in cancer immunotherapy, with a particular emphasis on the significance of utilizing pathological tissues to evaluate HLA class I molecules expressed in cancer cells.</jats:p>

収録刊行物

  • HLA

    HLA 103 (5), 2024-05

    Wiley

参考文献 (138)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ